NCT01914081

Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside

Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: St. Boniface Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if resveratrol can improve heart function and quality of life. Although, population studies have revealed that a mild to moderate intake of red wine reduces cardiovascular disease risk in humans, clinical studies that evaluate the potential heart benefits of resveratrol in patients with non-ischemic cardiomyopathy have not been previously reported. Accordingly, this research is being done because it will fill this deficiency in the information available in the literature and establish the clinical benefits of resveratrol in patients with this type of heart disease.

Detailed description

The investigators will conduct a randomized double blinded placebo controlled study of 40 adults (≥18 to 90 years old). Twenty (20) subjects will be included in the placebo arm, and 20 in the treatment arm. Patients will be randomly allocated to receive placebo or resveratrol. After randomization, the two groups of subjects will be followed up in exactly the same way, and the only differences between the care they receive will be those intrinsic to the treatment being compared. The randomization will minimize allocation bias, balancing both known and unknown prognostic factors, in the assignment of treatments.

Conditions

• Dilated Cardiomyopathy

Interventions

Type	Name	Description
OTHER	Resveratrol	Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
OTHER	Placebo	Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period

Timeline

• Start date: 2018-10-09
• Primary completion: 2019-11-01
• Completion: 2020-11-01
• First posted: 2013-08-01
• Last updated: 2018-11-14

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study